{[(4-Methoxyphenyl)methyl]sulfamoyl}dimethylamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: {[(4-Methoxyphenyl)methyl]sulfamoyl}dimethylamine
• 英文别名: 1-[(dimethylsulfamoylamino)methyl]-4-methoxybenzene
• 化学式: C₁₀H₁₆N₂O₃S
• mdl: MFCD02188293
• 分子量: 244.31
• InChiKey: AUSZDLKOZYWKIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  67
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'OREXINE DE TYPE 3-AMINO PYRROLIDINE ET PIPÉRIDINE MACROCYCLIQUE
  申请人：MERCK SHARP & DOHME

  公开号：WO2022109117A1

  公开（公告）日：2022-05-27

  The present invention is directed to 3-amino pyrrolidine and piperidine macrocyclic compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及3-氨基吡咯烷和哌啶大环化合物，其为促进荷尔蒙受体的激动剂。本发明还涉及所述化合物在潜在的神经和精神障碍和疾病的治疗或预防中的用途，其中荷尔蒙受体参与其中。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在的预防或治疗荷尔蒙受体参与的疾病中的用途。
• [EN] 5-ALKYL PYRROLIDINE OREXIN RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'OREXINE 5-ALKYL-PYRROLIDINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2020167706A1

  公开（公告）日：2020-08-20

  The present invention is directed to 5-alkyl pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.